CSF2 and urinary bladder cancer: To confirm the observed cytolytic potency of ICVB-1042, primary dissociated tumor cells from glioblastoma, lung cancer, bladder cancer, and breast cancer were assessed, comparing ICVB-1042 to our engineered versions of clinical stage OVs being tested for these specific indications (Ad5-GM-CSF, Ad5-Δ24-RGD, and Ad11p/Ad3, respectively).